DonCorleone77
Posted - 2 days ago
$REPL Replimune Group expects cash to fund operations into 2Q26 As of March 31, 2024, cash, cash equivalents and short-term investments were $420.7 million, as compared to $583.4 million as of fiscal year March 31, 2023. The decrease was primarily related to cash utilized in operating activities in advancing the Company's clinical development plans. Based on the current operating plan, the Company believes that existing cash, cash equivalents and short-term investments, as of March 31, 2024 will enable the Company to fund operations into the second half of 2026.
DonCorleone77
Posted - 2 days ago
$REPL Replimune Group reports 2024 EPS ($3.24), consensus ($3.27) "We have exciting milestones in the coming months, including sharing the investigator-assessed 12-month IGNYTE data at ASCO and then the official primary analysis by independent central review later in the second quarter," said Sushil Patel, Ph.D., CEO of Replimune. "Importantly, the design of our Phase 3 confirmatory IGNYTE-3 clinical trial has been agreed with the FDA, with patient enrollment planned to initiate in the second half of the year prior to the submission of our BLA for RP1. We also completed a successful Type C meeting with the FDA to align on our CMC plans ahead of the intended BLA. These are all critical steps as we plan for our next phase as a commercial stage company and, pending FDA approval, prepare to bring our first oncolytic immunotherapy to patients with advanced skin cancer."
Stock_Titan
Posted - 2 days ago
$REPL Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
https://www.stocktitan.net/news/REPL/replimune-reports-fiscal-fourth-quarter-and-year-ended-2024-kjh32c3g2odu.html
Mrs_BlackINKEconomics
Posted - 04/28/24
Is $OCEA phase 2 data out Tuesday too? I’m in $REPL but looks like there are a few phase two data dumps Tuesday 🤔
Mrs_BlackINKEconomics
Posted - 04/26/24
I’m sorry friends, I missed all the fun in the 2nd half of the week 😢, work stuff 🤷♀️ Here’s a few I like for next week!
$FAST especially calls, insiders added the selloff dip 🤔 $VHAI had a setup eod and even though it’s a scary penny stock it has potential. The one warning is they’re about a week or two away from earning a letter of noncompliance.
$REPL has phase two data on Monday. High risk reward ratio. $LVS calls look great here as a rebound.
$BYND calls for the runup to ER, then maybe even for the ER, last one pushed a big short term move
Mrs_BlackINKEconomics
Posted - 04/22/24
$REPL phase 2 data on the catalyst calendar for this month 👀 https://blackinkeconomics.com/calendar-free/. Runup to the event, maybe a lotto ticket for the event. We’ll see! ⏱️⏱️⏱️
pray007
Posted - 04/22/24
$REPL $SLS
precise
Posted - 04/21/24
$SLS Let me get this one on record. 📉 I smell cooked data. Reminds me of $REPL
rxptgh
Posted - 04/21/24
$REPL trading below cash Baker brothers 🤔 May open up position
rxptgh
Posted - 04/21/24
$REPL I like what I see here
YoloAlfred
Posted - 1 month ago
$REPL Inducement grants issued before readout 🤔🤔🤑🤑🤑🤑
YoloAlfred
Posted - 1 month ago
$REPL 🤔🤔🤔🤔🤔🤔
cryptocurrency666
Posted - 1 month ago
$REPL @kornsolana $korn
DonCorleone77
Posted - 1 month ago
$REPL 2 of 2 - Replimune Group presents interim results from ARTACUS trial of RP1 monotherapy ....Of note, a patient treated with RP1 for CSCC also had a complete response of a new primary basal cell carcinoma which appeared post baseline. There was no evidence of allograft rejection including of hepatic and lung allografts. RP1 monotherapy was well tolerated, and the safety profile was similar to the profile in non-immunocompromised patients with advanced skin cancers. Additional biomarker data collected showed an increase in CD+8 T, a type of immune cell, and an increase in the expression of PD-L1, after treatment suggesting immune activation.
DonCorleone77
Posted - 1 month ago
$REPL 1 of 2 - Replimune Group presents interim results from ARTACUS trial of RP1 monotherapy Replimune Group announced the presentation of interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid organ or hematopoietic cell transplants at the AACR 2024 Annual Meeting in San Diego. The results were initially presented late last year at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. In the study, treatment with RP1 as monotherapy, for up to 25 doses, resulted in an overall response rate of 34.8% with most responses ongoing as of the data cutoff date of September 18, 2023. In the evaluable patient population, 20 had cutaneous squamous cell carcinoma and three had merkel cell carcinoma....
Stock_Titan
Posted - 1 month ago
$REPL Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
https://www.stocktitan.net/news/REPL/interim-results-from-the-artacus-clinical-trial-of-rp1-monotherapy-cnbn66pmtqub.html
Stock_Titan
Posted - 1 month ago
$REPL Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://www.stocktitan.net/news/REPL/replimune-announces-inducement-grants-under-nasdaq-listing-rule-5635-ku6ramo46dyp.html
precise
Posted - 03/26/24
$REPL Founder and CEO out. Sorry but this whole pipeline is fooked. Replimune is not a systemic drug and Opdivo does all the work.
DonCorleone77
Posted - 03/26/24
$REPL Replimune Group announces appointment of Patel to CEO, leadership transitions Replimune Group announced changes to its executive leadership team designed to support the Company's preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma. Sushil Patel, Ph.D., will succeed Philip Astley-Sparke as CEO effective April 1, 2024. Astley-Sparke will transition from his current role as CEO to Executive Chairman of the Board of Directors. Dr. Patel joined Replimune three years ago initially as Chief Commercial Officer and served most recently as Chief Strategy Officer. Additional changes include: Robert Coffin, Ph.D., Founder, President and Chief Research & Development Officer will move to an advisory role as Founder and Chief Scientist and will continue to serve on the Board of Directors. Paul Bullock is being appointed Chief Manufacturing Officer and will assume oversight of manufacturing and lead operations in Framingham...
Stock_Titan
Posted - 2 months ago
$REPL Replimune to Present at the American Association for Cancer Research Annual Meeting 2024
https://www.stocktitan.net/news/REPL/replimune-to-present-at-the-american-association-for-cancer-research-x3xbru7bzx5z.html
Stock_Titan
Posted - 2 months ago
$REPL Replimune to Present at Three Upcoming Investor Conferences
https://www.stocktitan.net/news/REPL/replimune-to-present-at-three-upcoming-investor-3gy3q1drjmvx.html
fibonacci6180
Posted - 02/27/24
$REPL Trading idea - Entry point > 8.9/61.80% https://youtube.com/shorts/zWO5jDX5mJ4 Chart time frame : B A) 15 min(1W-3M) B) 1 hr(3M-6M) C) 4 hr(6M-1year) D) 1 day(1-3years) Stock progress : B A) Keep rising over 61.80% resistance B) 61.80% resistance C) Hit the bottom D) Hit the top
Richtree
Posted - 02/27/24
$REPL no volume today.
RallyRaider
Posted - 3 months ago
$REPL reversal coming? Baker Bros increasing amidst uncertainty. Anyone following this? whats the deal?
clemsoncrew
Posted - 3 months ago
$REPL But really, EPS, operating expenses, income, is not relevant. What is the fact they have plenty of cash and like many biotechs focus is on the positive data they provided for the IGNYTE clinical trial https://www.globenewswire.com/news-release/2024/02/08/2825950/0/en/Replimune-Reports-Fiscal-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html
clemsoncrew
Posted - 3 months ago
$REPL In august they beat by 6% and stock was at 18 and went to 20. The last quarter they reported beating EPS by 13% and stock is only at 7.55???? Where do you think the analyst will go? What price do you expect they will come in at tomorrow? 18?17?15? Guess we will see.
DonCorleone77
Posted - 3 months ago
$REPL Replimune Group reports Q3 EPS (77c), consensus (93c) "The collective data for RP1 shows that it has the potential to be a safe and effective treatment option for patients with a range of different skin cancers in various treatment settings. We plan to submit a BLA for the treatment of patients with anti-PD1 failed melanoma in 2H 2024. Subsequently, we will explore the potential for additional submissions based on the evolving data from our multiple non-melanoma skin cancer studies," said Philip Astley-Sparke, CEO of Replimune. "We are excited about the data we have seen to-date with RP2 including as monotherapy in very difficult to treat tumors. Planning is underway for a clinical trial in advanced uveal melanoma as a foundational study for establishing a rare cancer franchise. Following the decision to reprioritize our pipeline, we have extended our cash runway to fund operations into 2H 2026, leaving us well positioned to bring our lead product to market."
Stock_Titan
Posted - 3 months ago
$REPL Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
https://www.stocktitan.net/news/REPL/replimune-reports-fiscal-third-quarter-2024-financial-results-and-ocd6e8t7atia.html
precise
Posted - 01/25/24
@tedevan @SwordfishTrader @BiotechAC @HellRot On the other end, people were buying $REPL calls before their major readout recently. Millions upon millions. Iv was 400%, study flopped. You can always find a case to cater to any bias your emotions guide you to. Best to just stay objective though and play the risk/reward accordingly.
